

Morphology-based classification of sickle cell disease and β -thalassemia using a low-cost automated microscope and machine learning

Pranav Shrestha^{1*}, Hendrik Lohse^{1,2}, Christopher Bhatla³, Heather McCartney⁴, Alaa Alzaki³, Navdeep Sandhu⁵, Pradip Kumar Oli⁶, Hongquan Li⁷, Manu Prakash⁸, Ali Amid³, Rodrigo Onell³, Nicholas Au³, Hayley Merkeley³, Videsh Kapoor³, Rajan Pande^{6,9}, Boris Stoeber^{1,10*}

¹Department of Mechanical Engineering, The University of British Columbia, 2054-6250 Applied Science Lane, Vancouver, British Columbia, V6T 1Z4, Canada.

²Department of Mathematics and Computer Science, Eindhoven University of Technology, Groene Loper 3, 5612 AE, Eindhoven, The Netherlands.

³Faculty of Medicine, The University of British Columbia, 317-2194 Health Sciences Mall, Vancouver, British Columbia, V6T 1Z3, Canada.

⁴Division of Hematology & Oncology, BC Children's Hospital, 4480 Oak Street, Vancouver, British Columbia, V6H 3V4, Canada.

⁵Adult Red Cell Disorders Program of BC and Yukon, St. Paul's Hospital, 1081 Burrard Street, Vancouver, British Columbia, V6Z 1Y6, Canada.

⁵Division of Hematology, Providence Health Care, 440-1144 Burrard Street, Vancouver, British Columbia, V6Z 2A5, Canada.

⁶Mount Sagarmatha Polyclinic and Diagnostic Center, Nepalgunj, Bheri Zone, Province no-5, Nepal.

⁷Department of Electrical Engineering, Stanford University, 350 Jane Stanford Way, Stanford, California, USA.

⁸Department of Bioengineering, Stanford University, 443 Via Ortega, Stanford, California, USA.

⁹Department of Internal Medicine, Bheri Hospital, Nepalgunj, Bheri Zone, Province no-5, Nepal.

¹⁰Department of Electrical and Computer Engineering, The University of British Columbia, 2332 Main Mall, Vancouver, British Columbia, V6T 1Z4, Canada.

* Corresponding authors (email: pranav.shrestha@alumni.ubc.ca; boris.stoeber@ubc.ca)

1 **Abstract**

2 Sickle cell disease (SCD) and β -thalassemia are the most common monogenic diseases,
3 disproportionately affecting low- and middle-income countries, where low-cost and accurate diagnostic
4 tools are needed to reduce the global disease burden. Although the sickling test is commonly used to
5 screen for the sickle mutation, it cannot distinguish between the asymptomatic sickle cell trait (SCT) and
6 SCD, or identify β -thalassemia. Here, we enhanced the inexpensive sickling test using automated
7 microscopy and morphology-based machine learning classification to detect SCD, trait conditions (SCT
8 and β -thalassemia trait) and normal individuals with an overall area under receiver operating curve,
9 sensitivity and specificity of 0.940 (95% confidence intervals: 0.938-0.942), 84.6% (84.2%-84.9%), and
10 92.3% (92.1%-92.4%), respectively. Notably, the sensitivity and specificity to detect severe disease (SCD)
11 was over 97% and 98%, respectively, thus establishing a low-cost automated screening option for
12 disease detection in low-resource settings. Furthermore, leveraging high-throughput microscopy, we
13 generated an open-access dataset comprising over 300,000 images with 1.5 trillion segmented cells
14 from 138 individuals in Canada and Nepal including individuals with sickle and/or β -thalassemia
15 mutations, to accelerate further research.

16 **Introduction**

17 Sickle cell disease (SCD) is linked with an estimated 300,000-400,000 births every year and a mortality
18 rate exceeding 50% in certain areas of low-income countries^{1,2}. SCD is caused by a mutation in the gene
19 encoding hemoglobin β -globin subunit (HBB) resulting in a variant form of hemoglobin (HbS or sickle
20 hemoglobin). HbS causes red blood cells (RBCs) to distort into rigid “sickled” cells that can lead to
21 blockage of blood vessels (vaso-occlusion)^{1,3,4}, hemolysis, inflammation and progressive organ
22 damage^{4,5}. β -thalassemia is another inherited disease most commonly caused by point mutations in
23 HBB, resulting in either a reduced (β^+) or absent (β^0) synthesis of β chains of hemoglobin⁶. SCD is an
24 umbrella term for a combination of inherited diseases, including sickle cell anemia (homozygous HbSS)
25 and compound heterozygous sickle cell disease (HbS/ β -thalassemia, HbS/C, etc.). Inheritance of a
26 mutated gene from only one parent results in clinically asymptomatic, but carrier forms, such as sickle
27 cell trait (SCT; HbAS) and β -thalassemia trait (HbA/ β -thalassemia)⁷, which are usually more prevalent
28 than disease forms⁵. Screening for trait conditions (SCT and β -thalassemia trait) is also essential to

29 prevent the variant genes from being unknowingly transferred to children, potentially even as severe
30 disease forms.

31 Globally, HbS has the highest prevalence in sub-Saharan Africa, while HbS and β -thalassemia are both
32 prevalent in the Middle East, Mediterranean countries and South Asia⁴⁻⁶. Although the genetics and
33 hemoglobin biophysics of SCD, the first “molecular disease”⁸, have been extensively studied⁴, and
34 promising new techniques such as CRISPR-Cas9 gene editing for SCD and β -thalassemia have been
35 clinically tested⁹, there is still an unmet need to overcome the diagnostic barrier in low-resource
36 settings, where the burden of the disease is disproportionately high^{10,11}. Access to screening, caregiver
37 education and treatment options greatly improve quality of life and life expectancy of people with SCD,
38 and reduce childhood mortality by up to 90%^{1,12}. However, the burden of the disease is highest in
39 resource-constrained regions of low- and middle-income countries, with limited access to such
40 screening and treatment options. To enable timely and equitable diagnosis, low-cost and point-of-care
41 detection techniques are required in such low-resource settings to supplement or replace expensive
42 clinical laboratory techniques¹¹.

43 Gold standard tests for detecting most hemoglobinopathies like SCD and β -thalassemia include
44 hemoglobin (Hb) electrophoresis and high performance liquid chromatography (HPLC), which rely on
45 separating different variants of hemoglobin based on charge¹³. Hb HPLC is run on expensive equipment
46 in clinical laboratories by highly trained personnel, thus is not suitable for disease detection in
47 rural/remote or resource-constrained settings. Conventional low-cost alternatives, such as the sickling
48 test and Hb solubility test, detect the presence of HbS, but do not differentiate between SCT and SCD. In
49 the sickling test, blood is sealed between a microscope slide and a coverslip with a reagent that causes
50 deoxygenation (hypoxia), which induces sickling of RBCs for individuals with SCT and SCD^{7,13}. The
51 solubility test relies on the principle that HbS is insoluble in a high molarity phosphate buffer when
52 deoxygenated, resulting in a turbid solution (positive test for SCT and SCD)⁷.

53 Recently, novel approaches for detecting SCD have been developed or commercialized. Two
54 commercially available lateral-flow assays, HemoTypeSC and Sickie SCAN, detect HbS and variant
55 hemoglobin C (HbC), with reported sensitivity and specificity of over 92%¹⁴⁻²⁰. A low-cost paper-based
56 electrophoresis platform, the Gazelle Hb variant test, has also been commercialized to detect HbS, HbC
57 and β -thalassemia²¹. The lateral flow assays and the Gazelle cost between \$2 to \$5 per test (with an
58 additional one-time cost of \$1200 for the Gazelle portable reader), and are around an order of

59 magnitude costlier per test than the sickling test. Despite the importance of screening for β -thalassemia
60 (including β -thalassemia trait) in areas with high prevalence of both HbS and β -thalassemia, none of the
61 commercialized low-cost techniques (except Gazelle) detect β -thalassemia.

62 The morphological differences between sickled and round RBCs can be observed through microscopy,
63 which makes digital microscopy, augmented with machine learning, a potentially powerful tool for
64 disease identification. Most machine learning approaches thus far focus on identifying sickle cells in
65 microscopy images of peripheral blood smears, using techniques such as semantic segmentation²², or
66 classification on segmented cells from datasets using lightweight models (*e.g.* support vector machine
67 multi-class classifiers)²³ or deep convolutional neural networks²⁴. Although high accuracy of 98-99% has
68 been demonstrated using such techniques, sickle cells are usually only observed in peripheral blood
69 smears for SCD samples and not for SCT samples, thus preventing the use of such techniques to screen
70 for trait conditions. To overcome this limitation, another approach analysed microscopy images of the
71 sickling test, instead of peripheral blood smears. SCD and SCT were distinguished based on
72 morphological differences between cells using high and low concentrations of a sickling reagent, but this
73 technique required using two reagent concentrations and a custom microfluidic chamber²⁵.

74 Furthermore, most of these machine-learning based techniques have only been validated on thousands
75 of cells, thus highlighting a key challenge with these techniques - *i.e.* having limited annotated data for
76 training models. Although transfer learning, data augmentation and lightweight model architectures can
77 be used to work with small datasets²³, high-throughput microscopy can potentially generate large image
78 datasets and aggregation of morphological data can be utilized to avoid annotating at the single cell
79 level (when patient-level ground truth is available).

80 Here, we introduce an augmented version of the inexpensive sickling test using low-cost automated
81 microscopy and machine learning to detect SCD, SCT and β -thalassemia (Fig. 1a). We address the main
82 shortcomings of the sickling test (inability to distinguish between SCT and SCD, inability to detect β -
83 thalassaemia, and requirement of trained personnel to find sickle cells under a microscope), while
84 retaining its strengths (cost-effectiveness, basic sample preparation using one concentration of the
85 sickling reagent and easily available consumables, no requirement for staining or fixing cells, and
86 reliance on the morphology of RBCs for detection). Using high-throughput low-cost microscopy, we
87 generated a large open-access dataset of microscopic images of blood cells from de-identified samples
88 collected at clinical sites in Canada and Nepal, suitable for statistical analysis and machine learning. Our

89 classification approach is based on morphological differences between groups, relying on differences in
90 cell shapes between normal and sickled cells, differences in the level of sickling between SCD and SCT,
91 and differences in cell shape and size between normal and β -thalassemia trait. The study aims to enable
92 inexpensive and automated screening of SCD and trait conditions (SCT, β -thalassemia trait), and improve
93 access to screening in low-resource settings.

94 **Results**

95 **High-throughput automated microscopy of sickling test and creation of** 96 **open-access image dataset**

97 A total of 138 participants were recruited in Nepal and Canada: 30 without β -globin disorders (HbAA), 23
98 with β -thalassemia trait (HbA/ β -thalassemia), 45 with SCT (HbAS), and 40 with SCD (11 HbS/ β -
99 thalassemia and 29 HbSS). We modified the sample preparation protocol of the conventional sickling
100 test for high-throughput imaging and cell segmentation (more details in Methods). For each participant,
101 3-6 microscope slides (with 2 coverslips each) were prepared (Fig. 1a) and 225 images were captured
102 per coverslip in around 4 minutes by the Octopi microscope^{26,27}, with automated slide scanning and
103 automated focusing (Fig. 1b). Two hours after sample preparation, RBCs from normal (HbAA; Fig. 1c)
104 and β -thalassemia trait (HbA/ β -thalassemia; Fig. 1d) participants appeared unchanged to the eye, while
105 hypoxia-induced sickling was observed (Fig. 1e-g) for the majority of RBCs from SCD participants (HbS/ β -
106 thalassemia and HbSS), and for a fraction of RBCs from SCT participants (HbAS). The process of sickling,
107 facilitated by the polymerization of HbS, depends on factors such as HbS concentration, temperature
108 and rate of deoxygenation^{28,29}. We followed consistent sample preparation and imaging protocols, such
109 that major differences between sickling of different samples resulted from differences in HbS
110 concentration, *i.e.* between SCT and SCD. Imaging 1001 coverslips from 138 participants, around
111 220,000 images were captured 2 hours after sample preparation and around 1.2 trillion cells were
112 segmented using Cellpose 2.0³⁰ for statistical analysis and morphology-based machine learning
113 classification. All the de-identified microscopic images (raw and processed), cell segmentation data, and
114 calculated morphological parameters for images captured at 2 hours and other parameter settings (*e.g.*
115 other time instances, other temperature configurations, time-series data) are publicly available in an
116 open-access database³¹.

117 **Sickling under hypoxia**

118 The reagent in the sickling test (sodium metabisulphite) and the sealed wet preparation produces an
119 environment of reduced oxygen or hypoxia, which induces sickling in RBCs with HbS (*i.e.* for SCT and
120 SCD). The resolution of imaging (pixel size of 1.85 μ m for monochromatic camera) using 20 \times objective
121 microscopy was sufficient to observe sickling at the cellular level (Fig. 2a and Supplementary Videos 1
122 and 2). Sickling of RBCs produced detectable changes in some morphological parameters over time,
123 even at the level of a single image, containing aggregated data from around 3000 cells (Fig. 2b-g and
124 Supplementary Video 3). As an example for a participant with SCD, within a 50 minute time period, the
125 distribution of area remained nearly constant (Fig. 2b), the perimeter distribution changed slightly (Fig.
126 2c), and the distributions of major axis, minor axis, roundness, and eccentricity changed considerably
127 (Fig. 2d-g). The time evolution of the morphological parameters reflected the dynamics of RBC sickling,
128 *e.g.* the roundness peak (Fig. 2f) shifted from closer to 1 (round) to around 0.5 (elongated or sickled),
129 and the eccentricity peak (Fig. 2g) shifted from around 0.4 (less elongated) to around 0.9 (more
130 elongated or sickled), indicating that greater proportions of cells sickled over time.

131 **Morphological characterization at multiple scales**

132 Blood cells in microscopic images were segmented by fine-tuning a neural network-based model (Cyto
133 in Cellpose 2.0 using a human-in-the-loop approach³⁰. Based on the outlines of the segmented cells, 40
134 different parameters describing the size (*e.g.* area, perimeter), shape (*e.g.* roundness, eccentricity), and
135 intensity (*e.g.* mean intensity) of the cells were calculated (complete list in Supplementary information).
136 Different types of cells, including different variations of sickled cells (*e.g.* crescent, holly leaf, granular),
137 resulted in different values for morphological parameters (Fig. 2h). The morphological parameters
138 determined at the cellular level were aggregated at different levels or scales – group level (colored lines
139 in Fig. 3), donor level (Fig. 3a), slide level, coverslip level (Fig. 3b), and image level (Fig. 3c). For instance,
140 the frequency distribution of eccentricity, which describes how elongated a shape is, was calculated for
141 all the cells per donor or participant (aggregating data for nearly 6-10 million cells per participant; Fig.
142 3a). The distribution of eccentricity for normal (“AA” or HbAA) and β -thalassemia trait (“ABeta” or HbA/
143 β -thalassemia) were similar for image, coverslip and donor levels, with peaks close to 0.4 (less
144 elongated). The distribution of eccentricity of SCT (“AS” or HbAS) had two peaks at the group level
145 (colored lines in Fig. 3), indicating that a portion of the cells were sickled (high eccentricity) while the
146 rest were not (low eccentricity). As indicated by the variability of frequency distribution profiles, not all

147 images in the SCT group contained sickled cells. In contrast, the SCD group (*i.e.* HbSS and HbS/ β -
148 thalassemia) had prominent peaks at high values of eccentricity at all levels of analysis, indicating that
149 the images contained predominantly sickled or elongated cells. Overall, the curves for SCD were
150 markedly different from the rest, while curves for AA and ABeta, and for AS and the rest overlapped.

151 **Statistical differences between morphological parameters of different** 152 **groups**

153 To explore whether morphological differences existed between different groups, and to evaluate the
154 feasibility of morphology-based classification, we calculated statistical differences between frequency
155 distributions of different groups for all 40 morphological parameters. This statistical analysis used data
156 for morphological parameters aggregated at the coverslip-level, with a total of 1001 coverslips from 138
157 participants for 4 clinically relevant groups – AA (HbAA), ABeta (HbA/ β -thalassemia), AS (HbAS), and SCD
158 (HbS/ β -thalassemia and HbSS). For each morphological parameter, there were parameter ranges (or
159 bins in frequency distribution curves or features for classification) without significant differences (p-
160 value > 0.05) for morphologies of different classes (orange in heatmaps in Fig. 4). In contrast, there were
161 many bins or features that resulted in significant differences (p-value < 0.05) between morphologies of
162 different (or all) groups, thus being important features for morphology-based classification. For
163 example, there were significantly different occurrences of cells with major axis between 10.5 μ m and 11
164 μ m for 5 out of 6 combinations (grey box in Fig. 4a; and 4c-d), and with roundness between 0.89 and
165 0.92 for all 6 combinations (Fig 4e, 4g-h).

166 The statistical analysis results (Fig. 4) relate to observed and expected physical or morphological
167 characteristics of cells. Firstly, the differences between SCD and the other classes were larger than the
168 other combinations (indicated by lower p-values for C3, C5 and C6 than for other combinations in Fig
169 4a,d,e,h), mainly because the cells from SCD samples were predominantly sickled (indicated by shifted
170 peaks in frequency distribution in Fig. 4b,e), unlike cells from the other groups. However, since AA and
171 ABeta, and AS (to some extent) had round RBCs, there were many bins without significant
172 morphological differences for combinations C1, C2, C4 (Fig. 4a,e). Regardless, even for these 3
173 combinations, there existed bins with significant morphological differences, likely due to the presence of
174 some sickled cells in AS, and the variation in shape (poikilocytosis) and size (anisocytosis) of RBCs
175 expected in ABeta³².

176 To compare the 40 different morphological parameters with respect to their relevance for sample
177 classification, the top bins or features for each morphological parameter were evaluated (Fig. 4i,j).
178 Considering the minimum p-values for each combination of each morphological parameter (Fig. 4j),
179 almost all the parameters (236/240) had features with significant differences (Fig. 4j). Generally, non-
180 dimensional morphological parameters (red lines in Fig. 4i-j), such as roundness, eccentricity, normalized
181 area, *etc.*, produced more significant differences than other parameters, such as area, perimeter, *etc.*
182 Additionally, non-dimensional parameters are robust and independent of imaging modalities, and thus
183 were selected for classification. Overall, based on statistical analyses, there were morphological
184 differences between the 4 groups at multiple bins for all 6 combinations, suggesting that morphology-
185 based classification, particularly using frequency distribution from non-dimensional parameters, is
186 feasible.

187 **Morphology-based machine learning classification**

188 Coverslip-level frequency distribution of 19 non-dimensional morphological parameters were used for
189 machine-learning classification, using 80:20 participant-wise splits of training and testing data, which
190 were iteratively randomized 1000 times to obtain 95% confidence intervals (CI) of performance metrics.
191 Different groups were considered (details in Methods): *3Gp*, *3GpSc*, and *4Gp*. For the different cases,
192 confusion matrices and receiver operating characteristic (ROC) curves of top classifiers are provided in
193 Fig. 5. Performance metrics (class-wise and overall) for the top 5 classifiers in each case are provided in
194 Fig. 6 (more metrics in Tables S1-S3 of Supplementary information).

195 The area under the ROC curve (AUC or AUROC) relates to the probability that a classifier will rank a
196 randomly chosen positive case higher than a randomly chosen negative case³³. For *3Gp*, the top
197 classifier, quadratic support vector machine (QSVM), was able to discriminate the three classes typically
198 considered during HbS screening (Fig. 5a,d, 6d; upright triangles in Fig. 6a-c). The overall or macro-
199 averaged AUC, sensitivity, and specificity were 0.962 (95% CI: 0.961-0.963), 0.890 (0.888-0.892), and
200 0.945 (0.944-0.946), respectively. Traditionally, the sickling test cannot distinguish between SCT (AS) and
201 SCD, but in this case (*3Gp*), the top machine learning classifier distinguished AA (and ABeta), AS and SCD
202 with class-wise AUC (one vs. all) of 0.961 (0.96-0.963), 0.928 (0.925-0.93) and 0.997 (0.997-0.997),
203 respectively (Fig. 5d, 6d).

204 For *3GpSc*, the overall AUC, sensitivity and specificity for the top classifier (QSVM) were 0.940 (0.938-
205 0.942), 0.846 (0.842-0.849), and 0.923 (0.921-0.924), respectively (Fig. 5e, 6e, and inverted triangles in

206 Fig. 6a-c). The class-wise AUC for AA, trait (ABeta & AS) and SCD were 0.922 (0.919-0.925), 0.901 (0.898-
207 0.903), and 0.998 (0.998-0.998), respectively. For most of the top 5 classifiers (Fig. 6e), the sensitivity for
208 detecting disease and trait conditions were higher than for AA, indicating that most of the individuals
209 with trait or disease conditions would be identified during screening, and such individuals could be
210 followed up with confirmatory diagnostic tests.

211 For *4Gp*, the top classifier, subspace discriminant (SSD), was able to discriminate 4 groups (AA, ABeta,
212 AS, SCD) with a macro-averaged AUC of 0.921 (0.919-0.923), sensitivity of 0.763 (0.76-0.767), and
213 specificity of 0.921 (0.92-0.922) (Fig. 5c,f, 6f; squares in Fig. 6a-c). Different misclassification
214 penalties/costs can also be applied depending on the requirements of screening tools, *e.g.* higher
215 penalties for misclassification of trait or disease conditions than normal conditions increased the
216 sensitivity of detecting ABeta and AS (Fig. 6g). Additionally, feature selection can reduce computational
217 resource requirement with minimal effect on classifier performance, *e.g.* selecting the top 77 features
218 based on statistical analysis (Fig. 6h) resulted in comparable classification performance to that using all
219 570 features from 19 morphological parameters (Fig. 6f).

220 Notably, the sensitivity for detecting SCD was high (> 97%) in almost all the cases regardless of group
221 divisions, indicating that most of the severe disease cases were detected by the classifiers. This was
222 consistent with results from statistical analysis (Fig. 4) and observations of morphological differences in
223 microscopic images (Fig. 1).

224 Discussion

225 The low-cost sickling test, which is traditionally unable to distinguish between SCT and SCD and unable
226 to detect β -thalassemia, was augmented to detect individuals with/without SCD and trait conditions
227 (including β -thalassemia) with an overall sensitivity and specificity of 84.6% (95% CI: 84.2%-84.9%), and
228 92.3% (92.1%-92.4%), respectively (with sensitivity to detect only SCD of 97.3%). Such an augmentation
229 of the simple sickling test can enable accurate identification (>97% sensitivity) of people with severe
230 disease who require treatment and medical attention, while also screening for individuals with trait
231 conditions including β -thalassemia (85% sensitivity) who can be informed of the risks of passing variant
232 genes to children. Furthermore, the portable microscope can be implemented in different levels of
233 healthcare facilities without requiring a sophisticated laboratory/clinical setting. Moreover, the same

234 automated microscope can potentially be used for detecting other diseases relying on microscopy, such
235 as malaria²⁶ and tuberculosis³⁴.

236 The use of high-throughput automated microscopy for morphology-based classification provides
237 benefits to diagnostics in low-resource settings, allows expert review, and represents a powerful tool for
238 generating large training data sets for the development of advanced classification algorithms. Firstly,
239 automation can be implemented for device operation, slide scanning, and disease detection, reducing
240 the need for highly skilled personnel in low-resource settings. Secondly, if needed, the microscopic
241 images of blood cells can be examined by specialists (*e.g.* hematologists, hematopathologists, laboratory
242 technicians) to validate test results, similar to analysing a conventional sickling test for sickled cells to
243 screen for HbS or a peripheral blood smear for poikilocytosis or anisocytosis of RBCs to screen for β -
244 thalassemia. Furthermore, morphological characterization performed at coverslip-, donor-, or group-
245 levels can aggregate information and statistics of millions to trillions of cells, thus enabling richer
246 analysis at a scale orders of magnitude greater than with individual inspection of images. Such
247 morphological and aggregated characterization of cells relates to physical and observable differences
248 between cells of different groups. Thus, these morphological parameters serve as meaningful inputs to
249 machine-learning based classification and can enhance the interpretability of the classification process
250 and results, which is important for health-care related machine learning applications^{35,36}. Lastly, high-
251 throughput imaging enabled the creation of an open-access image dataset with hundreds of thousands
252 of images and trillions of segmented cells with ground truth diagnosis from Hb HPLC, which can be used
253 in the future to further improve classification performance, as segmentation/classification algorithms
254 improve over time. Furthermore, the same dataset can be used for disease detection using other
255 approaches not considered here, such as semantic segmentation or object detection.

256 In comparison with other low-cost tests, the overall sensitivity and specificity to detect phenotypes for
257 HbS and β -thalassemia were (ClinicalTrials.gov Identifier: NCT05506358): Gazelle Hb variant test (97.0%
258 & 99.3%), HemoTypeSC (74.4% & 94.4%), and Sickle SCAN (75.0% & 94.7%)^{37,38}. In terms of cost, the
259 other point-of-care techniques are 2-10 times more expensive than the augmented sickling test for
260 running 10,000-100,000 tests (Fig. 7), where the costs for the augmented sickling test include a one-time
261 cost for the automated microscope (< \$3,000), and inexpensive readily-available consumables (<\$0.5 per
262 test) such as microscope slides, coverslips, powdered reagent, and distilled water. Furthermore, only the

263 Gazelle and the augmented sickling test can detect β -thalassemia trait, which is critical to screen for in
264 regions with high prevalence of both HbS and β -thalassemia.

265 There are some limitations associated with the diagnostic technique and with the data used in this
266 study. Since the analysis relied on microscopic images, the morphological characterization was based on
267 two-dimensional (2D) snapshots of three-dimensional (3D) cell morphologies. Although most
268 round/healthy RBCs were flat and detected as round cells, some of these RBCs were on their sides,
269 resulting in round cells being detected as elliptocytic cells, a common limitation of blood cell imaging-
270 based diagnostic techniques. However, the occurrence of side-lying cells appeared to be negligible
271 compared to flat-lying RBCs, and such cells appeared in both training and testing datasets. At the chosen
272 configurations for time (2 hours) and temperature (room temperature), only a fraction of RBCs from SCT
273 samples sickled. Although this served as a basis for differentiating between SCT and SCD, and resulted in
274 high sensitivity to detect SCD, the incubation time or temperature can be increased to increase the
275 number of sickled cells for SCT, likely increasing the sensitivity to detect SCT. Furthermore, some
276 misclassifications between normal and β -thalassemia trait could possibly arise due to other factors such
277 as iron deficiency (not evaluated in this study), which can affect the RBC shape and size. Future studies
278 could include information such as ferritin level to account for other such confounding factors (*e.g.* iron
279 deficiency) that affect cell morphology. The duration of storage for blood samples also affects RBC
280 shape, and storage artifacts (some RBCs becoming echinocytic) were observed in some cells, which
281 could limit the classification performance, especially between normal and β -thalassemia trait samples.
282 Our study did not include β -thalassemia major patients because of their requirement for regular (*i.e.*
283 around monthly) blood transfusions, which would affect the test results. Additionally, as HbC mutation
284 is not encountered in Nepal, people with HbSC or HbAC were not included, and the algorithm therefore
285 was not trained to distinguish these conditions.

286 In summary, automated microscopy and morphology-based classification enhanced the performance of
287 the sickling test, and appears suitable to serve as a low-cost automated screening tool to detect sickle
288 cell disease and β -thalassemia in low-resource settings, where the disease burden is often the highest.

289 **Materials and Methods**

290 **Study design and participants**

291 The study (ClinicalTrials.gov Identifier: NCT05506358) was conducted in two countries – Canada and
292 Nepal. Blood collection and tests completed in Canada between September 2022 – March 2023 (at St.
293 Paul’s Hospital and BC Children’s Hospital, Vancouver), and in Nepal in November and December 2022
294 (at Mount Sagarmatha Polyclinic and Diagnostic Center, Nepalgunj). A total of 138 participants were
295 recruited (ages 2-74 years; 59% female, 41% male). The diagnoses for all participants, except normal
296 controls or healthy volunteers without known β -globin disorders, had been previously established by
297 hemoglobin high performance liquid chromatography (Hb HPLC). Confirmatory Hb HPLC was performed
298 on all participants and there were 30 normal (HbAA), 23 β -thalassemia trait (HbA/ β - thalassemia), 45
299 sickle cell trait (HbAS), and 40 sickle cell disease (11 HbS/ β -thalassemia and 29 HbSS) participants.
300 Participants older than 1 year were eligible. Exclusion criteria were pregnancy or blood transfusion
301 within 3 months. Informed consent was provided by the participants or parents, according to protocols
302 approved by institutional/national research ethics boards. The study protocols and documents were
303 reviewed and approved for the Canada study by the University of British Columbia-Providence Health
304 Care Research Institute (UBC-PHC REB Number: H21-01929), and for the Nepal study by the University of
305 British Columbia Clinical Research Ethics Board (UBC CREB Number: H22-00294) and Nepal Health
306 Research Council (NHRC Registration Number: 85/2022). Additionally, institutional certificates of
307 approval were obtained from the respective clinical sites where blood samples were stored and tested
308 (from UBC Children’s & Women’s Research Ethics Board and from Mount Sagarmatha Polyclinic and
309 Diagnostic Center).

310 **Blood sample collection**

311 Blood samples were collected by trained phlebotomists or clinical laboratory technologists from veins in
312 the antecubital fossa or the dorsum of the hand. In Canada, blood was drawn from blood collection
313 needles or butterfly needles directly into 4.0 mL vacuum blood collection tubes with K2 EDTA (BD
314 Vacutainer, Becton, Dickinson and Company). In Nepal, blood was drawn from hypodermic needles into
315 syringes, and immediately transferred to 3.0 mL disposable non-vacuum blood collection tubes with K3
316 EDTA (AV LabotUbe, AV Consumables). Blood samples were stored in a refrigerator at 4°C. Before
317 running any tests, blood samples were placed at room temperature for at least 30 minutes, and the
318 blood tubes were repeatedly inverted or placed in rotary mixers to gently mix the separated plasma and

319 settled blood cells. The blood samples were de-identified and associated with unique participant codes,
320 which were used as references for the blood tests and analyses. For the automated sickling test,
321 samples were prepared and imaged 1.4 ± 0.9 days (mean \pm standard deviation) after blood collection,
322 and the maximum time between blood collection and imaging was 2 days in Nepal and 4 days in Canada.

323 **Sample preparation for automated sickling test**

324 The sickling test is a well-established and commonly used screening technique to detect the presence of
325 hemoglobin S (HbS), but is not traditionally used to distinguish between sickle cell trait (SCT) and sickle
326 cell disease (SCD)^{7,13}. In our sample preparation method for the sickling test, red blood cells formed a
327 monolayer with minimum overlap and adequate spacing for high-throughput imaging and subsequent
328 image processing.

329 The sample preparation included the following steps:

- 330 1. Blood samples stored in EDTA tubes were taken out of storage (at 4°C) and placed at room
331 temperature for at least 30 minutes.
- 332 2. The reagent, 2% (w/w) sodium metabisulphite mixed in distilled water, was freshly prepared
333 and used up to around 3 hours after preparation. The reagent helped create a hypoxic
334 environment, which facilitated sickling.
- 335 3. The separated plasma and settled blood cells were gently mixed by inverting the tube or placing
336 it in a rotary mixer.
- 337 4. Whole blood and the reagent were pipetted at a 1:2 volume ratio (*e.g.* 150 μ L of whole blood :
338 300 μ L of reagent) into a separate tube or vial, and mixed by gentle inversions or in a rotary
339 mixer.
- 340 5. A drop of the mixture of blood and reagent (3 μ L to 3.3 μ L) was pipetted onto a glass
341 microscope slide, (VWR Vistavision 3" x 1" x 1 mm Microscope Slides, Cat. No. 16004-430).
- 342 6. A microscope coverslip (Fisherbrand Microscope Cover glass, 18 mm x 18 mm x 1 mm, 12542A,
343 Fisher Scientific, Pittsburgh, PA, USA) was gently placed on top of the drop of blood and reagent
344 to spread the mixture uniformly. The coverslip was gently lowered onto the mixture with the aid
345 of a toothpick to spread the mixture while minimizing the formation of bubbles. The size of the
346 coverslip (18 mm x 18 mm) was sufficient to spread the selected volume of the mixture (around
347 3 μ L) uniformly, forming a monolayer of cells and with minimal leakage from the coverslip
348 edges. A coverslip of a different size requires a different volume of the mixture to be dispensed.

- 349 7. The edges of the coverslip were sealed with a mixture of Vaseline, Lanolin and Paraffin (VALAP)
350 at a 1:1:1 mass ratio³⁹. The VALAP was melted in a glass petri dish placed on an electric hot plate
351 at a temperature between 100°C and 110°C, and a paint brush was used to collect the melted
352 VALAP and spread it on the edges of the coverslip. The VALAP solidified within a few seconds on
353 the coverslip and microscope slide to seal the mixture of blood and reagent.
- 354 8. The process was duplicated for each slide for the same blood sample, such that there were two
355 coverslips on each slide.

356 The sample preparation method for the sickling test from previous studies^{7,13} was modified to make it
357 suitable for imaging. Firstly, larger volumes of blood and reagent (150 µL : 300 µL) were mixed in a tube
358 or a vial, instead of mixing a small drop of blood with a small drop of reagent on the glass slide. Mixing
359 the contents in a tube was more consistent than mixing them on the glass slide. Secondly, the volume
360 ratio of blood to reagent was chosen as 1:2 (instead of the original 1:1 ratio) to avoid crowded cells and
361 rouleaux formation. Additionally, an inert and non-toxic sealant, VALAP, was used instead of nail
362 lacquers, which can contaminate the sample and sometimes created ghost cells (cells that have low
363 contrast in images, due to negligible hemoglobin content and ruptured cell membranes³²) at the
364 periphery of the coverslip. Lastly, imaging was performed at 2 hours after sample preparation, while the
365 samples were kept at room temperature (20-25°C), which ensured that most of the cells for individuals
366 with SCD sickled. We found that temperature affects the rate of sickling – increasing the temperature
367 increased the rate of sickling (Figures S2-S8 in Supplementary information). Imaging could potentially be
368 done earlier than 2 hours (*e.g.* 30 minutes to an hour) if samples were incubated at a higher
369 temperature (*e.g.* 37 °C), but temperature incubation was not chosen for this study due to the added
370 complexity and requirement for a well-functioning incubator, which may not be accessible in
371 remote/rural or low-resource settings.

372 **Automated high-throughput microscopy using Octopi**

373 The sealed wet preparation of blood mixed with 2% sodium metabisulphite was imaged with a low-cost
374 automated microscopy platform, Octopi (Open configurable high-throughput imaging platform for
375 infectious disease diagnosis in the field)²⁶. An infinity corrected 20× magnification objective lens
376 (Olympus UPLFLN 20x/0.5) was connected through a tube lens to a monochromatic camera (MER2-
377 1220-32U3M, Daheng Imaging). The monochromatic camera had a higher resolution than that of an
378 equivalent color camera, and was sufficient (pixel size: 1.85µm) for characterizing the morphology of

379 unstained cells in the prepared blood films. The microscope assembly included a 60 mm × 60 mm
380 motorized XY translational stage (HDS-U-XY6060SN, Heidstar Co., Ltd.) for automated slide scanning,
381 and a piezoelectric actuator to move the optical assembly for automated focusing. An LED matrix array
382 illuminated the sample, and the illumination intensity, timing and number of active LEDs were
383 programmatically controlled. All the functionality of the microscope, such as the computational
384 illumination, image capture, motorized slide translation and autofocus, were controlled using a
385 python-based graphical user interface (GUI), operated in Linux.

386 The field of view (FOV) of each image was 3,000 pixels by 3,000 pixels, corresponding to 0.9 mm by
387 0.9 mm. At each sample location, an image pair was captured, by sequentially illuminating the left and
388 right halves of the LED matrix for the individual images, so that the image pair was combined into a
389 higher contrast image (discussed later in ‘DPC image processing’). For each coverslip, a 15 by 15 grid of
390 image pairs or 225 image pairs were captured covering most of the area of the coverslip (with no
391 overlap between adjacent FOVs), which took roughly 4 minutes including regular autofocus after
392 every 3 image pairs. For each participant, 6 coverslips (3 slides prepared in Nepal) or 12 coverslips (6
393 slides prepared in Canada) were imaged 2 hours after sample preparation. Some coverslips were imaged
394 right after sample preparation, and at different time intervals (*e.g.* at configurations such as 1 hour, 3
395 hours, 4 hours, *etc.*). Time series imaging was also captured for some participants (*e.g.* 1000 image pairs
396 captured every 3 seconds) to visualize the sickling process of red blood cells with different HbS
397 concentrations. The images captured 2 hours after sample preparation were used for statistical analysis
398 and machine learning classification discussed here.

399 **Reference or gold standard test**

400 Hemoglobin high performance liquid chromatography (Hb HPLC) is one of the standard clinical methods
401 used for detecting sickle cell disease, β -thalassemia and other common hemoglobinopathies, and was
402 the reference test in Nepal and Canada⁷. All the blood samples were tested using the Hb HPLC
403 technique; the D10 Hemoglobin Testing System (Bio-Rad Laboratories Inc., California, USA) was used in
404 Nepal, and the BioRad Variant II (Bio-Rad Laboratories Inc., California, USA) was used in Canada. The
405 interpretations of the Hb HPLC results by medical laboratory technologists or hematopathologists served
406 as ground truth or diagnosis for the participants and was used for morphological characterization and
407 classification.

408 **Differential phase contrast (DPC) image processing**

409 The raw images from Octopi included image pairs illuminated from opposite illumination angles – one
410 image illuminated by the left half (with intensity I_L), and the other image illuminated by the right half
411 (with intensity I_R), of the programmable LED matrix. By normalizing the difference between the two
412 images, the intensity of differential phase contrast (DPC) image $I_{DPC} = 0.5 + (I_L - I_R)/(I_L + I_R)$ was
413 computed on a pixel-by-pixel basis. DPC imaging captures the phase gradient information from the two
414 images with opposite illumination angles, and does not rely on specialized objectives for phase
415 imaging⁴⁰. The blood cells in DPC images had sufficient contrast for morphological characterization (as
416 shown in Fig. 1), without the need for staining, which is typically required for peripheral blood smears³².
417 The DPC processing and most of the following image analyses were performed on a computing cluster
418 (Cedar, Compute Canada, Digital Research Alliance of Canada) due to the large scale of the image
419 dataset, which benefitted from computational resources and parallel computing on the cluster (mostly
420 using GPUs).

421 **Segmentation of blood cells using Cellpose 2.0**

422 Blood cells in the differential phase contrast (DPC) images were segmented using a generalist
423 segmentation algorithm, Cellpose 2.0³⁰, where a pre-trained neural network model (Cyto) was fine-
424 tuned using a human-in-the-loop approach. The human-in-the-loop approach used 125 image segments
425 (1,500 pixels × 1,500 pixels; 450 μm × 450 μm) from multiple donors and a recursive training approach.
426 Each image in the training cycle required user annotations for correcting existing outlines predicted by
427 the neural network and adding missing outlines of cells. The human-in-the-loop or iterative retraining
428 approach greatly reduces the number of user annotations required because annotations are corrected
429 in each retraining cycle, which iteratively improves the neural network model³⁰. The default pre-trained
430 neural-network model, Cyto, in Cellpose 2.0 already segmented round cells well, but the human-in-the-
431 loop approach was necessary to segment sickle cells, to avoid segmenting platelets, artifacts (*e.g.*
432 bubbles), and incomplete or obscured cells (*e.g.* overlapped cells and cells at the edges of the image).
433 Cell segmentation was the most computationally expensive process out of all the image processing
434 tasks, taking around 1-2 minutes for segmentation of around 4,000-6,500 cells per image using GPUs.
435 However, the overall computation time was significantly reduced by running parallel jobs on the Cedar
436 cluster.

437 **Calculating morphological and intensity parameters**

438 The outlines of segmented cells were saved by Cellpose 2.0 as text files, which were read by an image
439 processing software, ImageJ⁴¹ (or FIJI⁴²). The outlines were overlaid on the corresponding DPC images in
440 ImageJ to calculate morphological and intensity parameters of each cell. The parameters were
441 measured using ImageJ on the Cedar cluster, without the GUI or in “headless” mode. A total of 32
442 different morphological and intensity parameters were extracted for each cell, including basic
443 morphological parameters (*e.g.* area, perimeter, minor axis, major axis, etc.), non-dimensional
444 morphological parameters (*e.g.* circularity, aspect ratio, eccentricity, etc.), and intensity-based
445 parameters (*e.g.* mean intensity, skewness, kurtosis, etc.). Furthermore, 8 basic morphological
446 parameters were normalized by the mean values per image (*e.g.* normalized area, normalized
447 perimeter, etc.). A complete list of these parameters is provided in Supplementary information. The data
448 for each image (morphological and intensity parameters for every cell in the image) was stored in a
449 comma separated variable or .csv files, which was used for further processing (*e.g.* using MATLAB
450 programs).

451 **Morphological characterization**

452 Normalized frequency distribution of each morphological and intensity parameter was calculated using
453 the *histcounts* function in MATLAB, where the value in each bin $v_i = c_i/N$ represented the ratio of the
454 number of elements in the bin, c_i , to the total number of elements in the data, N . The frequency
455 distribution, representing relative probability of each morphological parameter, was calculated at
456 different levels or scales – at the image level, the coverslip level, the participant or donor level, and the
457 group or class level. For the analysis presented here, each frequency distribution was divided into 30
458 bins. The data for Canada and Nepal, imaged at 2 hours after sample preparation and stored at room
459 temperature, were combined to form 4 clinically relevant groups – AA, ABeta, AS, and SCD (including
460 SBeta and SS), and classification was performed on different combinations of these groups.

461 **Calculating statistical differences between different classes**

462 Differences between the frequency distributions of the 4 different groups were calculated in MATLAB
463 using one-way analysis of variance (ANOVA) and a post-hoc multiple comparison test (MCT), using
464 functions *anova1* and *multcompare*. ANOVA compares the means of several groups and tests the
465 hypothesis that they are equal against the alternative that they are not, indicating that at least one of
466 the means is different without specifying which pairs are different. MCT can be applied for a more

467 detailed pairwise comparison of the groups, by testing all the different combinations (6 combinations
468 for 4 groups). The most conservative method for multiple comparison, the Scheffe's method, was
469 applied as it is suitable for exploratory data analysis⁴³. MCT with Scheffe's method was used to calculate
470 p-values for all pair-wise combinations of the 4 groups at each bin of the frequency distribution of each
471 morphological parameter. The bins or regions of all non-dimensional morphological parameters that
472 resulted in the lowest p-values (highest differences) for each combination and for all combinations
473 (considering the geometric mean of p-values) were highlighted and also selected for classification with
474 feature selection.

475 **Morphology-based machine learning classification**

476 The frequency distribution at the coverslip level (where each coverslip had around 225 images),
477 describing the frequency of a parameter for all the cells under a coverslip for a particular participant,
478 was used for classification of the different groups. Based on statistical analysis and due to the
479 robustness of non-dimensional parameters, 19 non-dimensional morphological parameters were
480 selected out of the total 40 parameters, as described in Supplementary information. The DPC images
481 were not directly used for classification, but the morphological parameters were used instead because
482 classification using the frequency distribution of these parameters was computationally much less
483 resource-intensive and was also more interpretable than image-based classification – for instance, the
484 frequency distribution of morphological parameters for classification can be visualized and compared
485 statistically to check for differences between different classes.

486 Different groups were considered for classification: i) 3 groups (AA & ABeta, AS, SCD) typically
487 considered for screening only HbS without β -thalassemia (referred to as 3 groups or *3Gp*). In this case,
488 β -thalassemia trait (ABeta) was not identified separately from normal (AA), thus *3Gp* classification is
489 suitable either in regions with low prevalence of β -thalassemia, or in regions with high β -thalassemia
490 prevalence with supplemental low-cost screening tests for β -thalassemia, *e.g.* NESTROFT⁴⁴. ii) 3 groups
491 (AA, ABeta & AS, SCD) relevant for screening for both HbS and β -thalassemia, which combined the trait
492 conditions together and the SCD conditions together (referred to as 3 groups for screening or *3GpSc*).
493 The trait conditions, β -thalassemia trait (ABeta) and sickle cell trait (AS), were combined in *3GpSc*
494 because of similar outcomes for the two asymptomatic groups after screening, *i.e.* follow-up
495 confirmatory tests and genetic counselling for participants of reproductive age. iii) 4 clinically relevant

496 groups (AA, ABeta, AS, SCD), where only SBeta and SS were combined because of their similar
497 morphologies and clinical outcomes^{3,5,7} (referred to as 4 groups or 4Gp).

498 The Classification Learner App in MATLAB (using MATLAB 2023a) was used to test the performance of 30
499 different models or classifiers (based on support vector machine, decision tree, ensemble, neural
500 network, k-nearest neighbors, Naïve Bayes, and discriminant analysis – complete list in Supplementary
501 information). An 80:20 participant-wise split of training and testing data was used such that data from
502 each participant was either in the training split or the testing split, to prevent bias. The different classes
503 were balanced by up-sampling or randomly repeating some data for the minority classes, such that all
504 the classes had an equal number of images. Balancing the classes was important to remove bias towards
505 the majority class when training the models and when calculating performance metrics. During training,
506 10-fold cross-validation was performed to reduce overfitting of the training dataset. As an example for
507 the numbers of coverslips used for training and testing datasets, for the top classifier (subspace
508 discriminant) for classification into 4 groups, the mean (and standard deviation) numbers for training
509 (pre-balancing) was 798.8 (20.2) for all groups, 169.7 (6.0) for AA, 108.8 (0.4) for ABeta, 266.4 (6.4) for
510 AS, and 253.9 (7.4) for SCD, and for testing (pre-balancing) was 202.2 (20.2) for all groups, 42.3 (6.0) for
511 AA, 30.2 (0.4) for ABeta, 66.6 (6.4) for AS, and 63.1 (7.4) for SCD.

512 The performance metrics for validation (*e.g.* validation accuracy) obtained during training are not
513 presented here, and only the performance metrics for testing (*e.g.* testing accuracy) are presented. In
514 general, validation accuracy was higher than testing accuracy.

515 **Performance evaluation metrics**

516 The sensitivity (or recall), $Sens = TP / (TP + FN)$, is related to true positive (TP) and false negative (FN)
517 values, and is the ability to correctly classify an individual belonging to a certain class or group. The
518 specificity, $Spec = TN / (TN + FP)$, is related to true negative (TN) and false positive (FP) values, and is
519 the ability to correctly classify an individual not belonging to a certain class or group. Other performance
520 metrics, such as accuracy, positive predictive value (or precision), negative predictive value, and F1-
521 score, were also calculated and are tabulated for the top 5 classifiers in Supplementary information. For
522 multiclass problems, the performance metrics can be calculated, per class or group, by comparing one
523 group against all others (also known as one vs. all or one vs. rest), and the metrics were macro-averaged
524 by taking the mean of values for all individual groups.

525 **Classification metrics, repeatability and confidence intervals**

526 To test the repeatability of the classifications and to obtain confidence intervals for the evaluation
527 metrics, all classification models were iteratively trained and tested using random participant-wise splits
528 of the data (80 : 20 for training : testing) for 1,000 independent iterations. For each iteration, all
529 evaluation metrics were calculated for the testing data set: accuracy, sensitivity or recall, specificity,
530 positive predictive value or precision, negative predictive value, and F1-score calculated from the
531 confusion matrix, and the area under the curve (AUC) calculated from the receiver operating
532 characteristic (ROC) curve for each class (using one vs. all method; Fig. 5). Macro-averaged values of
533 these evaluation metrics were calculated to combine metrics from all classes. For all 1,000 iterations,
534 the mean and 95% confidence intervals (assuming normal distribution) were calculated for each
535 evaluation metric and the macro-averaged metrics. Additionally, data from all 1,000 iterations were
536 aggregated to calculate merged confusion matrices and ROC curves (individual class and macro-
537 averaged ROC curves).

538 **Open-access database**

539 In accordance with the approved research protocols and informed consent from participants, de-
540 identified data (such as de-identified images of blood films from Octopi, and processed data such as
541 segmentation outlines, morphological parameters, *etc.*) were deposited in an online public repository,
542 Federated Research Data Repository (FRDR), an open-access repository hosted by the Digital Research
543 Alliance of Canada. The link to the open-access dataset is provided <https://doi.org/10.20383/103.0916>³¹.
544 The dataset contains all the raw and processed data, and can be used to reproduce the results
545 presented here and also for further development of classification or morphological characterization of
546 sickle cell disease and β -thalassemia. The morphological and intensity parameters for data from Nepal
547 and Canada used in the current work (imaging at 2 hours at room temperature), and additional data for
548 additional configurations (*e.g.* different time settings, temperature settings, and time series data) are
549 available publicly in FRDR, stored as .csv files.

550 All the associated code (written in Python, MATLAB, or shell) for generating results presented here are
551 also available online in a public Github repository (<https://github.com/p-shrestha/erythroSight>).

552 **Acknowledgements**

553 We sincerely thank all the participants in the study for their invaluable blood samples; Ashik Gurung,
554 Mahesh Chaudhary, Ram Prabesh Tharu, Asmita Chaudhary, Sanjeev Chaudhary, and Shiva Gautam for
555 blood collection, tests and HPLC interpretation at Mount Sagarmatha Polyclinic and Diagnostic Center in
556 Nepal; Dr. Mykola Maydan for help with coordination, equipment setup and technical advice at the
557 pathology lab at BC Children's Hospital; all the phlebotomists and staff at BC Children's Hospital and St.
558 Paul's Hospital in Canada who helped with the study; Dinesh Raj Sapkota and Nura Basnet from Creating
559 Possibilities Nepal, and the UBC sickle cell team for helpful discussions; Dr. Roshan Chitrakar for
560 document translations; Erin Clary, Eugene Barsky, Jiarui Li, Paul Lesack, Tamanna Moharana, and Nick
561 Rochlin for helping set up the open-access dataset, cloud computing tools and data transfer protocols.
562 This research was undertaken, in part, with support from the Canada Research Chairs program, UBC
563 Health Innovation Funding Investment (HIFI) Awards, and the UBC Four Year Doctoral Fellowship (4YF)
564 program. The UBC Centre for Blood Research is home to the Naiman Vickars Endowment fund which has
565 provided funds for this project.

566 **Author contributions**

567 **Pranav Shrestha**: Conceptualization, Methodology, Software, Formal analysis, Investigation, Writing -
568 Original Draft, Writing - Review & Editing, Visualization, Funding acquisition. **Hendrik Lohse**: Software,
569 Investigation, Writing - Review & Editing. **Christopher Bhatla**: Conceptualization, Methodology,
570 Investigation, Writing - Review & Editing. **Heather McCartney**: Resources, Project administration. **Alaa**
571 **Alzaki**: Resources. **Navdeep Sandhu**: Resources, Project administration. **Pradip Kumar Oli**: Investigation,
572 Project administration. **Hongquan Li**: Methodology, Software, Resources, Writing - Review & Editing.
573 **Manu Prakash**: Methodology, Resources, Supervision, Writing - Review & Editing. **Ali Amid**:
574 Methodology, Resources, Writing - Review & Editing. **Rodrigo Onell**: Conceptualization, Methodology,
575 Writing - Review & Editing. **Nicholas Au**: Conceptualization, Methodology, Writing - Review & Editing.
576 **Hayley Merkeley**: Conceptualization, Methodology, Resources, Writing - Review & Editing. **Videsh**
577 **Kapoor**: Conceptualization, Methodology, Writing - Review & Editing, Funding acquisition. **Rajan Pande**:
578 Conceptualization, Methodology, Resources, Supervision. **Boris Stoeber**: Conceptualization,
579 Methodology, Formal analysis, Writing - Original Draft, Writing - Review & Editing, Supervision, Funding
580 acquisition.

581 **Competing interests**

582 Hongquan Li and Manu Prakash are co-founders, and Pranav Shrestha is an employee, of Cephla Inc.,
583 which is a spin-out company from Stanford University, deploying Octopi globally for disease diagnostics.

584 **References**


- 585 1. Kato, G. J. *et al.* Sickle cell disease. *Nat. Rev. Dis. Prim.* **4**, 18010 (2018).
- 586 2. Adepoju, P. Ghana takes on sickle-cell disease. *Lancet* **395**, 402 (2020).
- 587 3. Piel, F. B., Steinberg, M. H. & Rees, D. C. Sickle Cell Disease. *N. Engl. J. Med.* **376**, 1561–1573
588 (2017).
- 589 4. Rees, D. C., Williams, T. N. & Gladwin, M. T. Sickle-cell disease. *Lancet* **376**, 2018–2031 (2010).
- 590 5. Ware, R. E., de Montalembert, M., Tshilolo, L. & Abboud, M. R. Sickle cell disease. *Lancet* **390**,
591 311–323 (2017).
- 592 6. Galanello, R. & Origa, R. Beta-thalassemia. *Orphanet J. Rare Dis.* **5**, 11 (2010).
- 593 7. Wild, B. J. & Bain, B. J. Investigation of Variant Haemoglobins and Thalassaemias. in *Dacie and*
594 *Lewis Practical Haematology* 282–311 (Elsevier, 2017). doi:10.1016/B978-0-7020-6696-2.00014-
595 X.
- 596 8. Pauling, L., Itano, H. A., Singer, S. J. & Wells, I. C. Sickle Cell Anemia, a Molecular Disease. *Science*
597 (80-.). **110**, 543–548 (1949).
- 598 9. Frangoul, H. *et al.* CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β -Thalassemia. *N. Engl. J.*
599 *Med.* **384**, 252–260 (2021).
- 600 10. Simpson, S. Sickle cell disease: a new era. *Lancet Haematol.* **6**, e393–e394 (2019).
- 601 11. Odame, I. Perspective: We need a global solution. *Nature* **515**, S10–S10 (2014).
- 602 12. Gyamfi, J. *et al.* Evidence-based interventions implemented in low-and middle-income countries
603 for sickle cell disease management: A systematic review of randomized controlled trials. *PLoS*
604 *One* **16**, e0246700 (2021).
- 605 13. Bain, B. J. *Haemoglobinopathy Diagnosis. Haemoglobinopathy Diagnosis* (Wiley, 2006).

- 606 doi:10.1002/9780470988787.
- 607 14. Nnodu, O. E. *et al.* Implementing newborn screening for sickle cell disease as part of
608 immunisation programmes in Nigeria: a feasibility study. *Lancet Haematol.* **7**, e534–e540 (2020).
- 609 15. Steele, C. *et al.* Point-of-care screening for sickle cell disease in low-resource settings: A multi-
610 center evaluation of HemoTypeSC, a novel rapid test. *Am. J. Hematol.* **94**, 39–45 (2019).
- 611 16. Nnodu, O. *et al.* HemoTypeSC, a low-cost point-of-care testing device for sickle cell disease:
612 Promises and challenges. *Blood Cells, Mol. Dis.* **78**, 22–28 (2019).
- 613 17. Kakou Danho, J. B., Atiméré, Y. N., Koné, D., Yéo, D. D. & Couitchéré, L. Feasibility Study of the
614 “HemoTypeSC” Test for the Rapid Screening of Sickle Cell Disease in Côte D’Ivoire. *Adv. Hematol.*
615 **2021**, 1–7 (2021).
- 616 18. Kanter, J. *et al.* Validation of a novel point of care testing device for sickle cell disease. *BMC Med.*
617 **13**, 225 (2015).
- 618 19. McGann, P. T., Schaefer, B. A., Paniagua, M., Howard, T. A. & Ware, R. E. Characteristics of a
619 rapid, point-of-care lateral flow immunoassay for the diagnosis of sickle cell disease. *Am. J.*
620 *Hematol.* **91**, 205–210 (2016).
- 621 20. Segbena, A. Y. *et al.* Diagnostic accuracy in field conditions of the sickle SCAN® rapid test for
622 sickle cell disease among children and adults in two West African settings: the DREPATEST study.
623 *BMC Hematol.* **18**, 26 (2018).
- 624 21. Hasan, M. N. *et al.* Paper-based microchip electrophoresis for point-of-care hemoglobin testing.
625 *Analyst* **145**, 2525–2542 (2020).
- 626 22. de Haan, K. *et al.* Automated screening of sickle cells using a smartphone-based microscope and
627 deep learning. *npj Digit. Med.* **3**, 76 (2020).
- 628 23. Alzubaidi, L., Fadhel, M. A., Al-Shamma, O., Zhang, J. & Duan, Y. Deep Learning Models for
629 Classification of Red Blood Cells in Microscopy Images to Aid in Sickle Cell Anemia Diagnosis.
630 *Electronics* **9**, 427 (2020).
- 631 24. Xu, M. *et al.* A deep convolutional neural network for classification of red blood cells in sickle cell
632 anemia. *PLOS Comput. Biol.* **13**, e1005746 (2017).

- 633 25. D'Costa, C. *et al.* Differential sensitivity to hypoxia enables shape-based classification of sickle cell
634 disease and trait blood samples at point of care. *Bioeng. Transl. Med.* 2020.10.28.20221358
635 (2023) doi:10.1002/btm2.10643.
- 636 26. Li, H., Soto-Montoya, H., Voisin, M., Valenzuela, L. F. & Prakash, M. Octopi: Open configurable
637 high-throughput imaging platform for infectious disease diagnosis in the field. *bioRxiv* (2019)
638 doi:10.1101/684423.
- 639 27. Li, H. *et al.* Squid²: Simplifying Quantitative Imaging Platform Development and Deployment.
640 (2020) doi:<https://doi.org/10.1101/2020.12.28.424613>.
- 641 28. Li, X., Dao, M., Lykotrafitis, G. & Karniadakis, G. E. Biomechanics and biorheology of red blood
642 cells in sickle cell anemia. *J. Biomech.* **50**, 34–41 (2017).
- 643 29. Barabino, G. A., Platt, M. O. & Kaul, D. K. Sickle Cell Biomechanics. *Annu. Rev. Biomed. Eng.* **12**,
644 345–367 (2010).
- 645 30. Pachitariu, M. & Stringer, C. Cellpose 2.0: how to train your own model. *Nat. Methods*
646 2022.04.01.486764 (2022) doi:10.1038/s41592-022-01663-4.
- 647 31. Shrestha, P. *et al.* erythroSight: Open-access image dataset of blood cells from individuals with
648 sickle cell disease and/or beta-thalassemia or without known hemaglobinopathies, captured
649 using automated microscope Octopi. *Federated Research Data Repository* (2024)
650 doi:10.20383/103.0916.
- 651 32. Bain, B. J. Blood Cell Morphology in Health and Disease. in *Dacie and Lewis Practical*
652 *Haematology* 61–92 (Elsevier, 2017). doi:10.1016/B978-0-7020-6696-2.00005-9.
- 653 33. Fawcett, T. An introduction to ROC analysis. *Pattern Recognit. Lett.* **27**, 861–874 (2006).
- 654 34. Ogunlade, B. *et al.* Predicting tuberculosis drug resistance with machine learning-assisted Raman
655 spectroscopy. (2023).
- 656 35. Roberts, M. *et al.* Common pitfalls and recommendations for using machine learning to detect
657 and prognosticate for COVID-19 using chest radiographs and CT scans. *Nat. Mach. Intell.* **3**, 199–
658 217 (2021).
- 659 36. Zhang, A., Xing, L., Zou, J. & Wu, J. C. Shifting machine learning for healthcare from development

- 660 to deployment and from models to data. *Nat. Biomed. Eng.* (2022) doi:10.1038/s41551-022-
661 00898-y.
- 662 37. Shrestha, P. *et al.* Low-Cost Automated Microscopy and Morphology-Based Machine Learning
663 Classification of Sickle Cell Disease and Beta-Thalassemia in Nepal and Canada. *Blood* **142**, 790–
664 790 (2023).
- 665 38. Shrestha, P. *et al.* Evaluation of Low-Cost Techniques to Detect Sickle Cell Disease and β -
666 Thalassemia: An International Multi-Center Study. *SSRN* <https://ssrn.com/abstract=4908786>
667 (2024).
- 668 39. Valap Sealant. *Cold Spring Harb. Protoc.* **2015**, pdb.rec082917 (2015).
- 669 40. Tian, L., Wang, J. & Waller, L. 3D differential phase-contrast microscopy with computational
670 illumination using an LED array. *Opt. Lett.* **39**, 1326 (2014).
- 671 41. Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of Image Analysis
672 HHS Public Access. *Nat Methods* **9**, 671–675 (2012).
- 673 42. Schindelin, J. *et al.* Fiji: An open-source platform for biological-image analysis. *Nat. Methods* **9**,
674 676–682 (2012).
- 675 43. Lee, S. & Lee, D. K. What is the proper way to apply the multiple comparison test? *Korean J.*
676 *Anesthesiol.* **71**, 353–360 (2018).
- 677 44. Mamtani, M., Das, K., Jawahirani, A., Rughwani, V. & Kulkarni, H. Is NESTROFT sufficient for mass
678 screening for β -thalassaemia trait? *J. Med. Screen.* **14**, 169–173 (2007).
- 679


680 **Figures and captions**



681

682 **Fig. 1 | High-throughput imaging for morphology-based classification.** **a**, Sequence of sample preparation, imaging, cell
683 segmentation, and classification. **b**, Computer-aided design (CAD) renderings of automated microscope, Octopi, with enclosure
684 (left) and without some enclosure panels (right), showing different components. Picture of microscope during operation in Fig.
685 S1 in Supplementary information. **c-g**, Representative image segments from normal (AA = HbAA), β -thalassemia trait (ABeta =
686 HbA/ β -thalassemia), sickle cell trait (AS = HbAS), compound heterozygous sickle cell disease (SBeta = HbS/ β -thalassemia), and
687 homozygous sickle cell disease (SS = HbSS). Each image segment is $270 \mu\text{m} \times 270 \mu\text{m}$, cropped from $900 \mu\text{m} \times 900 \mu\text{m}$ images
688 (original FOVs). Images were taken two hours after sample preparation for the sickling test (blood + 2% sodium metabisulphite
689 in 1:2 volume ratio). White scale bars in images (**a**, **c-g**) are $100 \mu\text{m}$.


It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).



690

691 **Fig. 2 | Morphological changes during sickling and examples of cells from different groups.** **a**, Time series of image segments
 692 for a sample from a sickle cell disease (HbSS) participant, showing sickling at the cellular level; Solid and dashed arrows show
 693 cells before and after sickling, respectively; Time interval between adjacent images is 75 seconds; Scale bars (white) are 50 μm .
 694 **b-g**, Normalized frequency over time of different morphological parameters for an image (900 μm x 900 μm); Time series
 695 includes 1000 instances (or curves of frequency distribution), for a total time period of 3000 seconds; Number of cells = 2805 \pm
 696 17 (mean \pm standard deviation for 1000 instances); Morphological parameters changed between initial (yellow) and final (blue)
 697 time instances with varying degrees for area (**b**), perimeter (**c**), major axis (**d**), minor axis (**e**), roundness (**f**), and eccentricity (**g**).
 698 Supplementary video 3 shows the sickling of RBCs over time at the image level at 120 \times speed. **h**, Examples of cells with different
 699 values of morphological parameters, arranged in descending order of roundness (Rnd), ascending order of eccentricity (Ecc),
 700 and not sorted for circularity (Circ); Scale bar (black) in the first image is 10 μm .


It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/) .



701

702 **Fig. 3 | Morphological characterization at different scales.** **a**, Normalized frequency distribution of eccentricity for the different
703 groups (AA, normal; ABeta, β -thalassemia trait; AS, sickle cell trait; SCD, sickle cell disease) at the donor or participant level,
704 where each grey line represents aggregated results for all cells from each participant. **b**, Normalized frequency distribution of
705 eccentricity at the coverslip level, where each grey lines represent aggregated results for all cells in each coverslip. **c**,
706 Normalized frequency distribution of eccentricity at the image level, where each grey line represents aggregated results for all
707 cells in each image. The colored lines (**a-c**) represent aggregated results for the entire group. The number of cells (N_{cells}) in each
708 group are listed above all plots, while the number of donors (N_{donors}), coverslips ($N_{\text{coverslips}}$) and images (N_{images}) are listed inside
709 the plots.


It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).



710

711 **Fig. 4 | Statistical differences between frequency distributions of different groups at the coverslip level. a**, p-values for
 712 pairwise comparison of means of different groups at each bin using Scheffe's method, for morphological parameter major axis.
 713 **b**, Normalized frequency distribution (30 bins) of major axis for different groups, corresponding to heatmap (in **a**). **c**, Box plot
 714 for major axis between 10.5 μm and 11 μm (highlighted by grey boxes in **a** and **b**), indicating that there were significantly more
 715 cells for SCD with major axis between 10.5 μm and 11 μm than the other groups. **d**, Minimum overall p-values for all
 716 combinations (grey boxes in **a** and **b**) shown as blue (filled) circles, and minimum p-values for each combination (green boxes in

717 a) shown as green circles. e-h, Results for morphological parameter roundness, with grey boxes (in e and f) and data in g and h
 718 corresponding to roundness values between 0.89 and 0.92. i, Combinations for each morphological parameter with minimum
 719 overall (geometric mean) p-values (e.g. grey boxes in a and e appear at the corresponding indices of 4 and 20). j, Minimum p-
 720 values for each combination of all morphological parameters (e.g. green boxes in a and e appear at the corresponding indices of
 721 4 and 20). Orange in heatmaps (a, e, i, and j) indicates p value > 0.05 (difference not statistically significant), green boxes (in
 722 heatmaps) and green circles (d and h) indicate minimum p-values for the respective combination (row), and grey boxes (in
 723 heatmaps, and b and f) indicate minimum overall (geometric mean) p-values for all 6 combinations. Red horizontal lines in
 724 heatmaps (i, j) indicate non-dimensional morphological parameters. Box plots show median (line), 25th and 75th percentiles
 725 (box), non-outlier minimum and maximum (whiskers), and outliers (dots) for the normalized frequency in the corresponding
 726 bin. Notches that do not overlap have different medians at 5% significance level. A list of the morphological parameters (in i
 727 and j) is provided in Supplementary information.




728

729 **Fig. 5 | Morphology based classification into different groups.** a, Confusion matrix for classification into 3 groups (3Gp): AA &
 730 ABeta, AS, and SCD (SBeta and SS), where diagonal values represent percentages of correct predictions and off-diagonal values
 731 represent misclassifications. Classifier: quadratic support vector machine (QSVM). b, Confusion matrix for classification into 3
 732 groups suitable for screening both HbS and β -thalassemia (3GpSc): AA, trait conditions (ABeta and AS), SCD (SBeta and SS).
 733 Classifier: QSVM. c, Confusion matrix for classification into 4 groups (4Gp): AA, ABeta, AS, SCD (SBeta and SS). Classifier:
 734 subspace discriminant (SSD). Confusion matrices (a-c) are row-normalized. d-f, Receiver operating characteristic (ROC) curves
 735 for visualizing classifier performance at different thresholds, showing ROC curves for individual classes (one vs. all; colored
 736 curves) and macro-averaged ROC curves (black curves) for all groups. Dashed diagonal line (with AUC = 0.5) represents a


It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).

737 random guessing classifier that cannot discriminate between positive and negative classes. The areas under the receiver
 738 operating characteristic curve (AUC or AUROC) for individual and macro-averaged cases are shown. The confusion matrices and
 739 ROC curves show merged results (from 1000 iterations of randomized 80:20 participant-wise splits of training and testing data)
 740 for the testing sets only – validation accuracies from training sets were higher likely due to some overfitting, and are not shown.
 741 Coverslip-level frequency distribution (30 bins) data for 19 non-dimensional morphological parameters was used for
 742 classification.



743
 744 **Fig. 6 | Performance metrics for different classifiers on testing datasets.** a, Overall macro-averaged AUC (or AUROC) for 5 top
 745 classifiers (using 19 non-dimensional morphological parameters at the coverslip-level) to classify into 3 groups (3Gp) for
 746 screening only for HbS (AA & ABeta, AS, and SCD; purple upright triangle), 3 groups (3GpSc) for screening HbS and β -
 747 thalassemia (AA, ABeta & AS, and SCD; orange inverted triangle), and 4 groups (4Gp; AA, ABeta, AS, SCD; brown square). b,
 748 Overall macro-averaged sensitivity for the top 5 classifiers of the three cases. c, Overall macro-averaged specificity for the top 5

749 classifiers of the three cases. Error bars (a-c) represent 95% confidence intervals generated from 1000 iterations of randomized
750 participant-wise splits. d-f, Heatmaps showing overall (or macro-averaged) and individual (one vs. all) metrics (AUC, sensitivity
751 and specificity) of the top 5 classifiers for 3 groups (AA & ABeta, AS, and SCD; purple upright triangle; d), 3 groups for screening
752 (AA, trait, and SCD; orange inverted triangle; e), and 4 groups (AA, ABeta, AS, SCD brown square, f). g, Heatmaps showing
753 overall and individual metrics of the top 2 classifiers with different misclassification penalties (misclassifications of ABeta, AS, or
754 SCD as normal class AA had misclassification costs 10 times higher than for other misclassifications) h, Heatmaps showing
755 overall and individual metrics of the top 2 classifiers with feature selection (77 top features selected from statistical analysis).
756 Abbreviations – AUC, Area under the receiver operating characteristic curve; Sens, Sensitivity; Spec, Specificity; QSVM,
757 Quadratic support vector machine (SVM); LSVM, Linear SVM; WNN, Wide neural network; CSVM, Cubic SVM; TTN, Tri-layered
758 neural network; MGSVM, Medium Gaussian SVM; SSD, Subspace Discriminant; BT, Boosted tree.



759

760 **Fig. 7 | Cost performance plot for different detection techniques.** Comparison of different low-cost techniques, including
761 conventional sickling test, solubility test, Sickle SCAN, HemoTypeSC, Gazelle Hb variant test, and our augmented or automated
762 sickling test, against the reference test (Hb HPLC). Numbers indicate sensitivity (black) and specificity (grey) for low-cost
763 techniques against reference test (Hb HPLC). Numbers for sensitivity and specificity for the automated sickling test is for
764 detecting 3 groups (3GpSc) for screening HbS and β -thalassemia: normal (HbAA), triat (HbA/ β -thalassemia & AS), and SCD (HbSS
765 & HbS/ β -thalassemia).